273 related articles for article (PubMed ID: 15695335)
41. Axonal ER Ca
Mackay JP; Smith-Dijak AI; Koch ET; Zhang P; Fung E; Nassrallah WB; Buren C; Schmidt M; Hayden MR; Raymond LA
J Neurosci; 2023 May; 43(20):3743-3763. PubMed ID: 36944490
[TBL] [Abstract][Full Text] [Related]
42. The Sigma-1 Receptor Mediates Pridopidine Rescue of Mitochondrial Function in Huntington Disease Models.
Naia L; Ly P; Mota SI; Lopes C; Maranga C; Coelho P; Gershoni-Emek N; Ankarcrona M; Geva M; Hayden MR; Rego AC
Neurotherapeutics; 2021 Apr; 18(2):1017-1038. PubMed ID: 33797036
[TBL] [Abstract][Full Text] [Related]
43. Tetrabenazine is neuroprotective in Huntington's disease mice.
Wang H; Chen X; Li Y; Tang TS; Bezprozvanny I
Mol Neurodegener; 2010 Apr; 5():18. PubMed ID: 20420689
[TBL] [Abstract][Full Text] [Related]
44. Genetically-directed Sparse Neuronal Labeling in BAC Transgenic Mice through Mononucleotide Repeat Frameshift.
Lu XH; Yang XW
Sci Rep; 2017 Mar; 7():43915. PubMed ID: 28272512
[TBL] [Abstract][Full Text] [Related]
45. Modulation of SETDB1 activity by APQ ameliorates heterochromatin condensation, motor function, and neuropathology in a Huntington's disease mouse model.
Hwang YJ; Hyeon SJ; Kim Y; Lim S; Lee MY; Kim J; Londhe AM; Gotina L; Kim Y; Pae AN; Cho YS; Seong J; Seo H; Kim YK; Choo H; Ryu H; Min SJ
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):856-868. PubMed ID: 33771089
[TBL] [Abstract][Full Text] [Related]
46. Glycolysis inhibition decreases the levels of glutamate transporters and enhances glutamate neurotoxicity in the R6/2 Huntington's disease mice.
Estrada-Sánchez AM; Montiel T; Massieu L
Neurochem Res; 2010 Aug; 35(8):1156-63. PubMed ID: 20401690
[TBL] [Abstract][Full Text] [Related]
47. Adult neural progenitor cells from Huntington's disease mouse brain exhibit increased proliferation and migration due to enhanced calcium and ROS signals.
Xie W; Wang JQ; Wang QC; Wang Y; Yao S; Tang TS
Cell Prolif; 2015 Oct; 48(5):517-31. PubMed ID: 26269226
[TBL] [Abstract][Full Text] [Related]
48. Validating the use of M4-BAC-GFP mice as tissue donors in cell replacement therapies in a rodent model of Huntington's disease.
Döbrössy M; Klein A; Janghra N; Nikkhah G; Dunnett SB
J Neurosci Methods; 2011 Apr; 197(1):6-13. PubMed ID: 21295605
[TBL] [Abstract][Full Text] [Related]
49. Neuroprotective effects of psychotropic drugs in Huntington's disease.
Lauterbach EC
Int J Mol Sci; 2013 Nov; 14(11):22558-603. PubMed ID: 24248060
[TBL] [Abstract][Full Text] [Related]
50. Retinoic acid receptor beta protects striatopallidal medium spiny neurons from mitochondrial dysfunction and neurodegeneration.
Ciancia M; Rataj-Baniowska M; Zinter N; Baldassarro VA; Fraulob V; Charles AL; Alvarez R; Muramatsu SI; de Lera AR; Geny B; Dollé P; Niewiadomska-Cimicka A; Krężel W
Prog Neurobiol; 2022 May; 212():102246. PubMed ID: 35151792
[TBL] [Abstract][Full Text] [Related]
51. Intracellular Ca2+ signaling and human disease: the hunt begins with Huntington's.
Varshney A; Ehrlich BE
Neuron; 2003 Jul; 39(2):195-7. PubMed ID: 12873376
[TBL] [Abstract][Full Text] [Related]
52. Calcium homeostasis and mitochondrial dysfunction in striatal neurons of Huntington disease.
Lim D; Fedrizzi L; Tartari M; Zuccato C; Cattaneo E; Brini M; Carafoli E
J Biol Chem; 2008 Feb; 283(9):5780-9. PubMed ID: 18156184
[TBL] [Abstract][Full Text] [Related]
53. Hip1 and Hippi participate in a novel cell death-signaling pathway.
Wanker EE
Dev Cell; 2002 Feb; 2(2):126-8. PubMed ID: 11832235
[TBL] [Abstract][Full Text] [Related]
54. Correction: Differential Synaptic and Extrasynaptic Glutamate-Receptor Alterations in Striatal Medium-Sized Spiny Neurons of Aged YAC128 Huntington's Disease Mice.
PLOS Currents
PLoS Curr; 2017 Jul; 9():. PubMed ID: 28856061
[TBL] [Abstract][Full Text] [Related]
55. Enhanced Store-Operated Calcium Entry Leads to Striatal Synaptic Loss in a Huntington's Disease Mouse Model.
Wu J; Ryskamp DA; Liang X; Egorova P; Zakharova O; Hung G; Bezprozvanny I
J Neurosci; 2016 Jan; 36(1):125-41. PubMed ID: 26740655
[TBL] [Abstract][Full Text] [Related]
56. CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion.
Lee JM; Ramos EM; Lee JH; Gillis T; Mysore JS; Hayden MR; Warby SC; Morrison P; Nance M; Ross CA; Margolis RL; Squitieri F; Orobello S; Di Donato S; Gomez-Tortosa E; Ayuso C; Suchowersky O; Trent RJ; McCusker E; Novelletto A; Frontali M; Jones R; Ashizawa T; Frank S; Saint-Hilaire MH; Hersch SM; Rosas HD; Lucente D; Harrison MB; Zanko A; Abramson RK; Marder K; Sequeiros J; Paulsen JS; ; Landwehrmeyer GB; ; Myers RH; ; MacDonald ME; Gusella JF;
Neurology; 2012 Mar; 78(10):690-5. PubMed ID: 22323755
[TBL] [Abstract][Full Text] [Related]
57. Mitochondrial Permeability Transition, Cell Death and Neurodegeneration.
Baev AY; Vinokurov AY; Potapova EV; Dunaev AV; Angelova PR; Abramov AY
Cells; 2024 Apr; 13(7):. PubMed ID: 38607087
[TBL] [Abstract][Full Text] [Related]
58. Desipramine induces eryptosis in human erythrocytes, an effect blunted by nitric oxide donor sodium nitroprusside and N-acetyl-L-cysteine but enhanced by Calcium depletion.
Pan X; Giustarini D; Lang F; Rossi R; Wieder T; Köberle M; Ghashghaeinia M
Cell Cycle; 2023 Sep; 22(17):1827-1853. PubMed ID: 37522842
[No Abstract] [Full Text] [Related]
59. Dysfunction of cAMP-Protein Kinase A-Calcium Signaling Axis in Striatal Medium Spiny Neurons: A Role in Schizophrenia and Huntington's Disease Neuropathology.
Fjodorova M; Noakes Z; De La Fuente DC; Errington AC; Li M
Biol Psychiatry Glob Open Sci; 2023 Jul; 3(3):418-429. PubMed ID: 37519464
[TBL] [Abstract][Full Text] [Related]
60. Genetic Ablation of Inositol 1,4,5-Trisphosphate Receptor Type 2 (IP
Cunha-Garcia D; Monteiro-Fernandes D; Correia JS; Neves-Carvalho A; Vilaça-Ferreira AC; Guerra-Gomes S; Viana JF; Oliveira JF; Teixeira-Castro A; Maciel P; Duarte-Silva S
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445783
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
